Page 109 - 《中国药房》2024年20期

large vessel occlusions：systematic review and meta- FENG X Y，WANG M，GUO W J，et al. Efficacy and
analysis[J]. Stroke，2021，52（1）：308-312. safety of tenecteplase in the treatment of acute ischemic
[23] OLIVEIRA M，FIDALGO M，FONTÃO L，et al. Te‐ stroke：a meta-analysis[J]. China Pharm，2023，34（9）：
necteplase for thrombolysis in stroke patients：systematic 1119-1125.
review with meta-analysis[J]. Am J Emerg Med，2021，42： [35] SALAMATULLAH H K，BASHRAHIL B，ALGHAMDI
31-37. A M，et al. Efficacy and safety of tenecteplase in compari‐
[24] MA P J，ZHANG Y，CHANG L，et al. Tenecteplase vs. son to alteplase in acute ischemic stroke：a systematic re‐
alteplase for the treatment of patients with acute ischemic view and meta-analysis of randomized controlled trials[J].
stroke：a systematic review and meta-analysis[J]. J Neu‐ Clin Neurol Neurosurg，2023，233：107961.
rol，2022，269（10）：5262-5271. [36] SHEN Z Y，BAO N N，TANG M，et al. Tenecteplase vs.
[25] KATSANOS A H，PSYCHOGIOS K，TURC G，et al. alteplase for intravenous thrombolytic therapy of acute
Off label use of tenecteplase for the treatment of acute ischemic stroke：a systematic review and meta-analysis[J].
ischemic stroke：a systematic review and meta-analysis[J]. Neurol Ther，2023，12（5）：1553-1572.
JAMA Netw Open，2022，5（3）：e224506. [37] ZHANG X，WAN T F，CHEN J，et al. Tenecteplase versus
[26] REQUIAO L E，OLIVEIRA R S，REIS L S，et al. Short- alteplase for patients with acute ischemic stroke：a meta-
term efficacy outcomes of tenecteplase versus alteplase analysis of randomized controlled trials[J]. Aging（Albany
for acute ischemic stroke：a meta-analysis of 5 rando- NY），2023，15（24）：14889-14899.
mized trials[J]. Neurol India，2022，70（4）：1454-1459. [38] WANG Y，CAI X Y，FANG Q，et al. Efficacy and safety
[27] ABUELAZM M，SERI A R，AWAD A K，et al. The effi‐ outcomes of tenecteplase versus Alteplase for thromboly‐
cacy and safety of tenecteplase versus alteplase for acute sis of acute ischemic stroke：a meta-analysis of 9 rando-
ischemic stroke：an updated systematic review，pairwise， mized controlled trials[J]. J Neurol Sci，2024，458：
and network meta-analysis of randomized controlled trials 122912.
[J]. J Thromb Thrombolysis，2023，55（2）：322-338. [39] MA Y，XIANG H N，BUSSE J W，et al. Tenecteplase ver‐
[28] REHMAN A U，MOHSIN A，CHEEMA H A，et al. Com‐ sus alteplase for acute ischemic stroke：a systematic re‐
parative efficacy and safety of tenecteplase and alteplase view and meta-analysis of randomized and non-randomized
in acute ischemic stroke：a pairwise and network meta- studies[J]. J Neurol，2024，271（5）：2309-2323.
analysis of randomized controlled trials[J]. J Neurol Sci， [40] HUANG J，ZHENG H，ZHU X F，et al. Tenecteplase ver‐
2023，445：120537. sus alteplase for the treatment of acute ischemic stroke：a
[29] KOBEISSI H，GHOZY S，TURFE B，et al. Tenecteplase meta-analysis of randomized controlled trials[J]. Ann
vs. alteplase for treatment of acute ischemic stroke：a sys‐ Med，2024，56（1）：2320285.
tematic review and meta-analysis of randomized trials[J]. [41] SINGH A，SINGH M P，GAIKWAD N R，et al. Te‐
Front Neurol，2023，14：1102463. necteplase versus alteplase in acute ischemic stroke：a sys‐
[30] ROSE D，CAVALIER A，KAM W，et al. Complications of tematic review and meta-analysis[J]. Ann Neurosci，2024，
intravenous tenecteplase versus alteplase for the treatment 31（2）：132-142.
of acute ischemic stroke：a systematic review and meta- [42] WU N H，DOEPPNER T R，HERMANN D M，et al. Effi‐
analysis[J]. Stroke，2023，54（5）：1192-1204. cacy and safety of intravenous tenecteplase compared to
[31] WEI H，FU B，YANG C，et al. The efficacy and safety of alteplase before mechanical thrombectomy in acute ische-
intravenous thrombolysis with tenecteplase versus al‐ mic stroke：a meta-analysis[J]. J Neurol，2024，271（7）：
teplase for acute ischemic stroke：a systematic review and 3928-3941.
meta-analysis[J]. Neurol Sci，2023，44（9）：3005-3015. [43] GAO L，MOODIE M，MITCHELL P J，et al. Cost-
[32] LIANG H，WANG X，QUAN X M，et al. Different doses effectiveness of tenecteplase before thrombectomy for
of tenecteplase vs. alteplase for acute ischemic stroke ischemic stroke[J]. Stroke，2020，51（12）：3681-3689.
within 4.5 hours of symptom onset：a network meta- [44] HAJIAN K，ABDI DEZFOULI R，DARVISHI A，et al. Te‐
analysis of randomized controlled trials[J]. Front Neurol， necteplase in managing acute ischemic stroke：a long-term
2023，14：1176540. cost-utility analysis in Iran[J]. Expert Rev Pharmacoecon
[33] THE E Z，LIN N N，MATAR M，et al. Different dosing Outcomes Res，2023，23（1）：123-133.
regimens of tenecteplase in acute ischemic stroke：a net‐ [45] GAO L，PARSONS M，CHURILOV L，et al. Cost-
work meta-analysis of the clinical evidence[J]. Eur Stroke effectiveness of tenecteplase versus alteplase for stroke
J，2023，8（1）：93-105. thrombolysis evaluation trial in the ambulance[J]. Eur
[34] 凤心雨，王敏，郭文军，等. 替奈普酶治疗急性缺血性脑 Stroke J，2023，8（2）：448-455.
卒中疗效及安全性的 Meta 分析[J]. 中国药房，2023，34 （收稿日期：2024-04-09 修回日期：2024-09-22）
（9）：1119-1125. （编辑：孙 冰）

中国药房 2024年第35卷第20期 China Pharmacy 2024 Vol. 35 No. 20 · 2547 ·